For anyone still holding (I dont):
MCQ:
Biota Holdings
Biota reported a 2002 full year loss of $8.6m versus its 2001 loss of $0.7m. The majority of the
decline in revenues was associated with lower grants ($2.1m) and the continuing fall in
Relenza sales.
In 2003, Biota will receive the majority of the payments from GlaxoSmithKline (GSK) for its
licensing deal on Hepatitis C stemming from the acquired N.MAX technology. This is
estimated to be $4m in 2003 and will help offset the US$8m the company is spending on
research & development in the US over two years as part of the NuMAX acquisition.
Potential milestones for Biota over the next 12–18 months include:
· Agreement with GSK on the future of Relenza;
· US-based funding in the form of private equity for Biota Inc and/or grant funding in the US;
· A partner for new generation flu drug – FLUNET;
· A second collaboration from the N.MAX technology.
Success in these areas will help in the ‘rebuilding’ process for Biota. However, clinical trials
are likely to remain at least two to three years away. In other words, Biota’s current pipeline is
at a relatively early stage.
We retain our Underperform recommendation. Biota is undertaking a long rebuilding process
that may well produce collaborations and licensing deals along the way. However, the real end
game – commercial products (or even clinical trials) – remains some time away.
ASX Code:
BTA
Share Price:
$0.46
Short term:
Underperform
Long term:
Underperform
Risk factor:
Speculative
- Forums
- ASX - By Stock
- BTA
- A view....
A view....
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online